Who
Gunther Birznieks
SVP, Business Development
Company insider
Files Form 4 as: SVP, Business Development, Vanda Pharmaceuticals.
In numbers
- Trades disclosed
- 39
- Buys
- 0
- Sells
- 18
- Bought
- $0
- Sold
- $2.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Jan 2018
- Last trade
- 2 Mar 2026
- Last filed
- 4 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 4 Mar 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $351K42,431 at $8.27 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $351K42,431 at $8.27 | filing |
| 18 Feb 2026filed 19 Feb 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $128K26,941 at $4.76 | filing |
| 18 Feb 2025filed 20 Feb 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 5 Mar 2024filed 6 Mar 2024 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $36K8,684 at $4.13 | filing |
| 4 Mar 2024filed 6 Mar 2024 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $38K8,727 at $4.30 | filing |
| 16 Feb 2024filed 21 Feb 2024 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 3 Mar 2023filed 6 Mar 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $52K8,268 at $6.26 | filing |
| 2 Mar 2023filed 6 Mar 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $53K8,509 at $6.20 | filing |
| 16 Feb 2023filed 21 Feb 2023 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 16 Feb 2023filed 21 Feb 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —32,700 at $0.00 | filing |
| 26 Aug 2022filed 29 Aug 2022 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,250 at $0.00 | filing |
| 26 Aug 2022filed 29 Aug 2022 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $3,9001,250 at $3.12 | filing |
| 2 Mar 2022filed 2 Mar 2022 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $130K11,517 at $11.27 | filing |
| 1 Mar 2022filed 2 Mar 2022 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $46K4,084 at $11.19 | filing |
| 28 Feb 2022filed 2 Mar 2022 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 28 Feb 2022filed 2 Mar 2022 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —32,700 at $0.00 | filing |
| 2 Mar 2021filed 3 Mar 2021 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $302K16,620 at $18.19 | filing |
News
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramVNDA · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Gunther Birznieks; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.